# A Safety and Immune Response Study of 2 Experimental HIV Vaccines

> **NCT02404311** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 252 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** ALVAC-HIV
- **BIOLOGICAL:** Bivalent Subtype C gp120/MF59®
- **BIOLOGICAL:** ALVAC-HIV (vCP2438) Placebo
- **BIOLOGICAL:** Bivalent gp120/MF59® Placebo

## Key facts

- **NCT ID:** NCT02404311
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-02
- **Primary completion:** 2018-08-07
- **Final completion:** 2018-08-07
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2021-11-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02404311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02404311, "A Safety and Immune Response Study of 2 Experimental HIV Vaccines". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02404311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*